共 20 条
[1]
Leier C.V., Webel J., Bush C.A., The cardiovascular effects of the continuous infusion of dobutamine in patients with severe heart failure, Circulation, 56, pp. 468-472, (1977)
[2]
Liang C.S., Sherman L.G., Doherty J.U., Et al., Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine, Circulation, 69, pp. 113-119, (1984)
[3]
Unverferth D.V., Blanford M., Kates R.E., Leier C.V., Tolerance to dobutamine after 72 hours continuous infusion, Am J Med, 69, pp. 113-119, (1980)
[4]
Unverferth D.V., Magorien R.D., Altschuld R., Et al., The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy, Am Heart J, 106, pp. 29-34, (1983)
[5]
Leier C.V., Huss P., Lewis R.P., Unverferth D.V., Drug-induced conditioning in congestive heart failure, Circulation, 65, pp. 1382-1387, (1982)
[6]
Colucci W.S., Wright R.F., Braunwald E., New position inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical development, N Engl J Med, 314, pp. 296-299, (1986)
[7]
Hoyer D., Engel G., Berthold R., Binding characteristics of (+), (±), a,d (−)-(<sup>125</sup> idocyanopindolol) in guinea pig left ventricle membranes, Naunyn Schmiedeberg's Arch Pharmacol, 31, pp. 319-320, (1982)
[8]
Maskin C.S., Forman R., Sonnenblick E.H., Et al., Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure, Am J Cardiol, 51, pp. 177-182, (1983)
[9]
Bristow, Ginsburg R., Minobe W., Et al., Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts, N Engl J Med, 307, pp. 205-211, (1982)
[10]
Anderson K.E., Adrenergic mechanism in congestive heart failure, Acta Med Scand, 70, pp. 37-44, (1986)